Tvardi Therapeutics (NASDAQ:TVRD) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Tvardi Therapeutics (NASDAQ:TVRD) from a hold rating to a sell rating in a research report report published on Saturday.

Several other research analysts have also weighed in on the stock. BTIG Research restated a “buy” rating and set a $15.00 target price on shares of Tvardi Therapeutics in a research report on Wednesday. Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 29th. Finally, Lucid Cap Mkts upgraded Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Tvardi Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.50.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ TVRD opened at $3.02 on Friday. Tvardi Therapeutics has a one year low of $2.81 and a one year high of $43.65. The firm has a market capitalization of $28.33 million, a P/E ratio of -0.54 and a beta of 0.16. The company’s fifty day moving average is $3.71 and its two-hundred day moving average is $8.53.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.23).

Hedge Funds Weigh In On Tvardi Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC acquired a new position in Tvardi Therapeutics during the second quarter worth about $2,617,000. JPMorgan Chase & Co. purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at about $39,000. New York State Common Retirement Fund acquired a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $92,000. Marshall Wace LLP acquired a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $583,000. Finally, Slate Path Capital LP purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $16,427,000. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.